NCT04476017Phase 2Completed

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-03-25Actual
Enrollment · participants18Actual
Source updated2025-09-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.